schliessen
Diese Seite empfehlen
Interessant, oder?
Teilen Sie diese Seite auf Facebook, Google+ oder Twitter

schliessen
Aktuelle Umfrage
Wie, glauben Sie, wird der DAX am Ende dieser Woche - KW 18 - stehen?
Jetzt abstimmen!
Alle Umfragen ansehen
DAX ®11.781,13-0,25%TecDAX ®1.651,01-0,24%S&P FUTURE2.113,00+0,06%NASDAQ FUT4.529,25+1,06%
LYNX Broker
finanztreff.de

dpa-AFX: TetraLogic And Merck Enter Into Oncology Clinical Study Collaboration

| Quelle: dpa-AFX Analysen
WHITEHOUSE STATION (dpa-AFX) - TetraLogic Pharmaceuticals Corp. (TLOG) and Merck (MRK) announced they have entered into an oncology clinical study collaboration. The companies will collaborate on a Phase 1 study to evaluate the safety and efficacy of birinapant, TetraLogic's SMAC-mimetic, in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with relapsed or refractory solid tumors. The study is expected to begin in late 2015. KEYTRUDA and birinapant target different elements of cancer's block against the immune system. TetraLogic's birinapant (TL32711) is a potent, bivalent SMAC-mimetic that binds with differential affinity to multiple members of the IAP family in order to re-establish the immune system's ability to kill abnormal cells via an extracellular TNF signal. Merck's KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 (programmed death receptor-1) and its ligands, PD-L1 and PD-L2. The proposed collaboration is based on preclinical data that suggest SMAC-mimetics have the potential to enhance existing immuno-oncology agents, such as KEYTRUDA. As per the terms of the agreement, TetraLogic and Merck, through subsidiaries, will collaborate on an initial Phase 1 dose-escalation study of birinapant in combination with KEYTRUDA in patients with relapsed or refractory solid tumors. TetraLogic will sponsor and fund the study and Merck will provide KEYTRUDA. The companies have formed a Joint Development Committee to collaboratively oversee the conduct of the study. Results from the study will be used to determine the path for further clinical development of the combination. Copyright RTT News/dpa-AFX

Merck & Co.

XETRA 52,79 -1,29%
EUR 09:52:10 -0,69

zum Kursportrait AdHoc-Meldungen & Insidertrades
Werbung
Werbung
Werbung
Bid & Ask Newsletter kostenlos lesen! |DAX & Dow Handeln: 1 Punkt Spread |GOLD & Silber vor neuer RALLYE?!
+88% GEWINN mit EUR/USD?! |FreeTRADE- und FreeBUY-Aktion bis Ende März
Werbung

Börsenseminare – speziell für Privatanleger. 17. März – 19. Mai.

Hier informieren & anmelden!